Ccr7 bv421 a clone g043h7

LR‐DC, SA‐DC, LR + SA‐DC, and Mo‐DC, prior to or post‐stimulation with LPS, were stained with the following monoclonal antibodies: CD14 FITC‐A (clone M5E2), CD86 PerCP‐A (clone IT2.2), CD83 PE‐Cy7‐A (clone HBI5e), CD11c APC‐A (clone B‐ly6), HLA‐DR PerCP‐A (clone G46‐6), DC‐SIGN BV421‐A (clone DCN46) (all from BD Biosciences, San Jose, CA), and CCR7 BV421‐A (clone G043H7) (BioLegend, San Diego, CA). The FACSVerse instrument and the FACS Suite software (BD Biosciences) were used to acquire data. Corresponding isotype‐matched antibodies were used as negative controls. Detailed gating strategies for the DC can be found in Supplementary Figure S1A. The results show either the percentage of positive cells within a given population or the mean surface expression of receptors per cell defined as geometrical mean fluorescence intensity (MFI). Analysis was done with FlowJo Software (TreeStar, Ashland, OR) and Cytobank (Cytobank, Inc., Mountain View, CA).

RA-DC and Mo-DC were stained with the following monoclonal antibodies: CD14 FITC-A (clone M5E2), CD1d PE-A (clone CD1d42), CD86 PerCP-A (clone IT2.2), CD83 PE-Cy7-A (clone HBI5e), CD11c APC-A (clone B-ly6), CD103 PE-A (clone Ber-ACT8), HLA-DR PerCP-A (clone G46-6), DC-SIGN BV421-A (clone DCN46) (all from BD Biosciences, San Jose, CA, USA), and CCR7 BV421-A (clone G043H7) (BioLegend, San Diego, CA, USA). The FACSVerse instrument and the FACS Suite software (BD Biosciences) were used to acquire data. Corresponding isotype-matched antibodies were used as negative controls. Detailed gating strategies for the DC can be found in Figure S1A in Supplementary Material. The results show either the percentage of positive cells within a given population or the mean surface expression of receptors per cell defined as geometrical mean fluorescence intensity (MFI). Analysis was done with FlowJo Software (TreeStar, Ashland, OR, USA) and Cytobank (Cytobank, Inc., Mountain View, CA, USA).